Nick Paul Taylor

Biography for Nick Paul Taylor

Nick Taylor, Editor

Nick Taylor is a freelance journalist with more than six years' experience of reporting on the global biopharma industry. Since graduating with a biology degree from the University of York, Nick has written for numerous healthcare publications, including Nature BioPharma Dealmakers, Life Science Leader and Outsourcing-Pharma. You can contact him at ntaylor@fiercemarkets.com and follow him on Twitter at @NickPaulTaylor.

Articles by Nick Paul Taylor

Novartis and Google team up to commercialize 'smart' contact lenses

The deal gives Google a partner with healthcare experience to commercialize the glucose-recording contact lens technology it unveiled earlier this year.

Google-backed service provider gives clients direct control of robot-run lab

While virtual biotechs and the service providers that support them have been around for years, Transcriptic and rival West Coast startups think they can improve the model through automation. And having raised cash from Google's venture unit and struck deals with some elite academic centers, Transcriptic is now rolling out the next phase of its plan.

FDA adds recalls API as openFDA initiative gathers pace

The FDA is continuing to push ahead with its openFDA initiative, with this week's rollout of an application programming interface (API) for recall data coming a month after its adverse event system went live. And the regulator plans to maintain the pace throughout the rest of the summer.

Bioinformatics skills help Codexis strike $25M deal with GSK

Codexis strengthened its ties to small-molecule synthesis this week through a deal with GlaxoSmithKline. The agreement will see GSK pay $6 million upfront and more in milestones to license the platform.

Report: Development IT hit hard in Novartis cutbacks

Over the first few months of 2014, Novartis quietly began laying off workers, shedding an estimated 3,000 jobs in four months. Now BioSpace has provided details of where the ax has fallen and why, with development IT teams suffering heavy job losses.

Database provides fresh evidence of effect of diabetes drugs on Alzheimer's

This week a German team presented data from a database analysis study that found a link between a diabetes drug and a slight dip in the risk of developing Alzheimer's.

Illumina strikes sequencing deal with England's 100K Genome Project

When Illumina unveiled its HiSeq X Ten in January, the alignment between its capabilities and the needs of England's 100K Genome Project were clear. The project aims to sequence 100,000 genomes by 2017 for around $160 million, figures that only look achievable using the massive output and relatively low costs of the HiSeq X Ten. This week the tie-up became official.

Google creates new cash source for European biotech IT startups with $100M VC fund

After weeks of increasingly confident media speculation, Google has confirmed it is setting up an outpost of its venture capital wing in Europe. And with a brief to follow a similar strategy to the U.S. team that invested in Flatiron Health, DNAnexus and other biotech IT startups, the $100 million fund is a new source of capital for European life science innovators.

FDA warns Gilead over 'misleading' paid search link

The drug is approved for treating--not preventing--hepatitis B, prompting FDA to call the advert misleading.

After working to mimic the brain for 9 years, Numenta reflects on limitations of today's hardware

Although Numenta has made progress in creating apps that reproduce the brain, it thinks a fully functioning model is impossible without rethinking the underlying hardware.